Viatris led the way in the US respiratory space once again last summer, debuting generic competition to AstraZeneca’s Symbicort (budesonide/formoterol) following years of patent-litigation action over the inhaler brand’s intellectual property.
Six months or so after Viatris launched its Breyna version of Symbicort in partnership with Kindeva Drug Delivery, the originator’s...




